The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Roche has entered into an agreement with Evotec to fund the Phase II clinical development of a selective N-methyl-D-aspartate (NMDA) receptor antagonist, EVT 101, for patients with treatment ...

Why We Need Fast-Acting Anxiety Relief Now More Than Ever Anxiety isn’t just feeling nervous before a big event—it can be relentless, overwhelming, and even debilitating. Traditional treatments like ...

In a study published in Cell, a research team led by Zhu Shujia from the Center for Excellence in Brain Science and ...

In this study, recently published in Alzheimer's & Dementia, the authors investigated NMDA (N-methyl-D-aspartate receptors) receptors due to their importance in synaptic transmission and their ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). May affect or be affected by renally-excreted drugs (eg, triamterene, HCTZ, metformin, cimetidine, nicotine ...

The interplay of opiate and NMDA glutamate receptors may contribute to psychosis, cognitive function, alcoholism, and substance dependence. Ketamine and ethanol block the NMDA glutamate receptor.

NMDA receptors, members of the excitatory ionotropic glutamate receptor family, are essential to these processes. They regulate the strength of synaptic connections, playing a critical role in ...